A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to evaluate safety and tolerability and to determine
recommended Phase 2 dose (RP2D) of E7389-LF in combination with nivolumab in Phase 1b part,
and to evaluate objective response rate (ORR) of E7389-LF and nivolumab using RP2D in Phase 2
part in each tumor type.